About Roivant Sciences Ltd.

Roivant Sciences Ltd., founded in 2014, pioneered a unique biopharmaceutical model creating subsidiary companies ("Vants") to efficiently develop overlooked or deprioritized drug candidates. The company's innovative approach combines drug development with technology platforms to accelerate pharmaceutical R&D. ROIV stock price reflects the value of its diverse portfolio of subsidiaries and drug candidates at various development stages.

Led by CEO Matt Gline, Roivant has demonstrated ability to create significant value through its Vant model, with several successful subsidiary exits validating the approach. The management team combines pharmaceutical expertise with entrepreneurial thinking to identify opportunities and build focused companies around them. Leadership's strategic vision for transforming drug development through technology and novel business models has been instrumental in creating shareholder value and influencing ROIV stock price trajectory.

Roivant operates by forming subsidiaries around promising drug candidates or technology platforms, providing them with resources and expertise to advance development efficiently. The company's portfolio includes wholly-owned and partially-owned Vants developing therapies across multiple therapeutic areas, plus technology platforms enhancing drug discovery and development. With a proven track record of value creation through subsidiary development and monetization, diverse shots on goal across its portfolio, and innovative approaches to pharmaceutical R&D, ROIV offers investors a differentiated biotechnology investment with multiple potential value catalysts from clinical advancements, partnerships, and subsidiary transactions.